Veradermics MANE Change in Other Liabilities
Change in Other Liabilities at other companies
Other financials
Where this comes from
Reported directly by Veradermics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherOperatingLiabilities.
The official record: Veradermics ’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Veradermics 's change in other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Veradermics 's change in other liabilities?
- Veradermics (MANE) reported change in other liabilities of -$8K in Q1 2026.
- How has Veradermics 's change in other liabilities changed year-over-year?
- Veradermics 's change in other liabilities decreased by 14.3% year-over-year, from -$7K to -$8K.
- What does change in other liabilities mean?
- The net change in miscellaneous liabilities that do not fall under standard accounts payable or accrued expenses.
- How do you interpret change in other liabilities?
- An increase indicates rising non-debt obligations, while a decrease suggests the settlement of these liabilities.
- How does change in other liabilities compare across companies?
- Varies significantly by industry; biopharma companies often see fluctuations based on clinical trial milestone accruals.